An interventional study of Nalu Neurostimulation System for PNS and conventional medical management in Peripheral Neuralgia and Chronic Pain, sponsored by Nalu Medical, Inc.. Active, not recruiting at 13 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Nalu Medical, Inc. (part of Boston Scientific Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Chronic Pain by Boston Scientific Corporation — 3 open to participants now, 7 under way, none of them phase 3. Chronic Pain · Boston Scientific Corporation.
Among the 37 studies in Chronic Pain by Boston Scientific Corporation, this one is the 10th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2022, is one of 28 with no phase, and was the 33rd registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →3 of the 37 studies in Chronic Pain by Boston Scientific Corporation are open now, in 12 countries. Recruiting first, the newest first:
Boston Scientific Corporation · Sites in United States
Ages 18+
Boston Scientific Corporation · Sites in United States, Argentina, Australia and 13 more countries
Ages 18+
Boston Scientific Corporation · Sites in United States, Australia, Belgium and 11 more countries
Ages 18+
By country, each count listing its studies:
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2022.
This study's enrollment of 131 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 46 across the 32 interventional studies, 828 across the 5 observational. Of the 29 that completed or were terminated, 26 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Nalu Medical, Inc., one of the names counted as Boston Scientific Corporation. Under that name alone:
Nalu Medical, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
1 of the studies in Chronic Pain by Boston Scientific Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07190807Boston Scientific CorporationManaging Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Chronic Pain by Boston Scientific Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This post market study is being conducted to document the comparative effectiveness and safety of peripheral nerve stimulation plus conventional medical management versus conventional medical management alone in the treatment of chronic, intractable peripheral neuralgia of post-traumatic or post-surgical origin. This is a prospective, minimal risk, multi-center, randomized control trial.
Multi-center, prospective, open-label, randomized controlled trial (RCT) comparing PNS plus CMM with CMM alone. Subjects will be randomized to receive:
Arm 1: Nalu Neurostimulation System for PNS plus CMM Arm 2: CMM alone Consented subjects will receive a baseline evaluation and then be randomized 2:1 into one of two arms: 1) PNS+CMM arm or 2) CMM arm. Subjects assigned to Arm 1 will undergo a trial implant period using best clinical practices. Those subjects who pass the trial implant will receive the permanent implant. At the 3-month end point, subjects in Arm 2 will be given the option to crossover into Arm 1 beginning with a trial implant. All Arm 1 patients receiving a permanent implant will be followed for a total of 36 months after permanent implantation. Arm 2 patients who do not crossover will be followed for a total of 36 months from randomization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
peripheral nerve stimulator plus conventional medical management
Device: Nalu Neurostimulation System for PNS · Other: conventional medical management
Control arm conventional medical management only
Other: conventional medical management
The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
Also known as: Nalu PNS
Conventional medical management
Effectiveness: Responder Rates Between Groups
Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the BPI-Q5 (NRS).
Time frame: 3-months
Functional Outcomes: Change in Oswestry Disability Index (ODI) Score From Baseline to 3-month
Change in patient reported ODI from baseline with comparison between groups. The ODI is a patient reported questionnaire used to measure functional disability and daily living impact. The ODI consists of ten topics, each scored from 0-5- pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life (optional), social life and traveling. The total score is used to calculate the percentage of disability from 0-100% and categorized as minimal, moderate, severe disability, crippled and bed bound. A lower score, compared to baseline, indicates improvement in ODI.
Time frame: 3 months
Functional Outcomes: Change in Beck's Depression Inventory (BDI) Score From Baseline
Change in patient reported depression from baseline with comparison between groups. The BDI is scored from 0-63. A lower score at follow-up compared to baseline, indicates an improvement in depression symptoms and mood.
Time frame: 3-months
Functional Outcomes: Brief Pain Inventory (BPI; Interference)
Brief Pain Inventory is a validated questionnaire to measure pain severity and how pain interferes with daily functioning. Pain Interference (general activity, mood, walking, work, relationships, sleep, enjoyment of life; 0-10 scale where, 0=Does not interfere and 10= completely interferes)
Time frame: 3-months
Functional Outcomes: Brief Pain Inventory (BPI; Severity)
Brief Pain Inventory is a validated questionnaire to measure pain severity using a 0-10 rating scale where, 0= no pain and 10= pain as bad as you can imagine.
Time frame: 3-months
Functional Outcomes: Quality of Life Using the EQ-5D-5L
The EQ-5D-5L is a standardized, self-reported questionnaire used to measure health related quality of life across 5 dimension i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels from no problems to extreme problems. This produces a 5-digit code which is converted to an index value based on the health of the general population where a higher score indicates better health (0-1).
Time frame: 3-months
Recruitment commenced on 23 February 2022 and completed on 29 March 2023. Recruitment carried out at 12 pain management centers across the United States.
| Milestone | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management |
|---|---|---|
| Started | 58 | 31 |
| Completed | 43 | 29 |
| Not completed | 15 | 2 |
| Withdrew: Physician decision | 3 | 0 |
| Withdrew: Trial failure | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 2 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Missed visit | 3 | 0 |
Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the BPI-Q5 (NRS).
| Participants | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management |
|---|---|---|
| Effectiveness: Responder Rates Between Groups | 36 | 1 |
Change in patient reported ODI from baseline with comparison between groups. The ODI is a patient reported questionnaire used to measure functional disability and daily living impact. The ODI consists of ten topics, each scored from 0-5- pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life (optional), social life and traveling. The total score is used to calculate the percentage of disability from 0-100% and categorized as minimal, moderate, severe disability, crippled and bed bound. A lower score, compared to baseline, indicates improvement in ODI.
| percentage of disability | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management |
|---|---|---|
| Functional Outcomes: Change in Oswestry Disability Index (ODI) Score From Baseline to 3-month | 22.7 ± 15.4 | 40.0 ± 17.9 |
Change in patient reported depression from baseline with comparison between groups. The BDI is scored from 0-63. A lower score at follow-up compared to baseline, indicates an improvement in depression symptoms and mood.
| score on a scale | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management |
|---|---|---|
| Functional Outcomes: Change in Beck's Depression Inventory (BDI) Score From Baseline | 6.40 ± 7.0 | 9.0 ± 7.86 |
Brief Pain Inventory is a validated questionnaire to measure pain severity and how pain interferes with daily functioning. Pain Interference (general activity, mood, walking, work, relationships, sleep, enjoyment of life; 0-10 scale where, 0=Does not interfere and 10= completely interferes)
| score on a scale | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management |
|---|---|---|
| Functional Outcomes: Brief Pain Inventory (BPI; Interference) | 2.32 ± 2.05 | 5.73 ± 2.02 |
Brief Pain Inventory is a validated questionnaire to measure pain severity using a 0-10 rating scale where, 0= no pain and 10= pain as bad as you can imagine.
| score on a scale | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management |
|---|---|---|
| Functional Outcomes: Brief Pain Inventory (BPI; Severity) | 2.93 ± 1.95 | 6.41 ± 1.79 |
The EQ-5D-5L is a standardized, self-reported questionnaire used to measure health related quality of life across 5 dimension i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels from no problems to extreme problems. This produces a 5-digit code which is converted to an index value based on the health of the general population where a higher score indicates better health (0-1).
| score on a scale | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management |
|---|---|---|
| Functional Outcomes: Quality of Life Using the EQ-5D-5L | 0.78 ± 0.13 | 0.63 ± 0.14 |
Collected over 3-months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PNS Therapy Plus Conventional Medical Management | 0/58 (0%) | 2/58 (3.4%) | 11/58 (19%) |
| Conventional Medical Management | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| Event | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management |
|---|---|---|
| Hospitalization for diverticulitisGastrointestinal disorders | 1/58 | 0/31 |
| Laparoscopic Endometriosis ExcisionReproductive system and breast disorders | 1/58 | 0/31 |
| Event | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management |
|---|---|---|
| Skin irritation including redness, itching and bumpinessMusculoskeletal and connective tissue disorders | 5/58 | 0/31 |
| Infection at implant siteInfections and infestations | 3/58 | 0/31 |
| Migration (IPG or Lead)Product Issues | 3/58 | 0/31 |
The baseline analysis population is a modified intent to treat (mITT) population as pre-defined in the Statistical Analysis Plan (SAP). The mITT is defined as "all randomized subjects receiving a permanent implant and having an implant at the time of analysis in the Active Arm and all randomized subjects in the Control Arm".
| Age, Continuous(years) | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management | Total |
|---|---|---|---|
| Mean | 57.6 ± 11.5 | 57.03 ± 12.5 | 57.4 ± 11.8 |
| Sex: Female, Male(Participants) | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management | Total |
|---|---|---|---|
| Female | 32 | 22 | 54 |
| Male | 14 | 9 | 23 |
| Ethnicity (NIH/OMB)(Participants) | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 9 |
| Not Hispanic or Latino | 37 | 24 | 61 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Race (NIH/OMB)(Participants) | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 37 | 25 | 62 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 4 | 9 |
| Years since diagnosis(years) | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management | Total |
|---|---|---|---|
| Mean | 4.1 ± 4.8 | 6.3 ± 6.5 | 5 ± 5.6 |
| Areas of Pain(Participants) | PNS Therapy Plus Conventional Medical Management | Conventional Medical Management | Total |
|---|---|---|---|
| Low Back | 24 | 14 | 38 |
| Knee | 8 | 8 | 16 |
| Shoulder | 7 | 3 | 10 |
| Foot/Ankle | 7 | 6 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2022 to primary completion in Dec 2023, 21 months.
Results were first posted in Nov 2026, 2 years 11 months after primary completion.
Of 83 industry-sponsored interventional studies with no phase under Chronic Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's 21 months is close to that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jun 2027, on Nov 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.